Population-Based Phase II Trial of Stereotactic Ablative Radiotherapy (SABR) for Up to 5 Oligometastases: SABR-5
BMC Cancer - United Kingdom
doi 10.1186/s12885-018-4859-7
Full Text
Open PDFAbstract
Available in full text
Date
October 4, 2018
Authors
Publisher
Springer Science and Business Media LLC